- Home
- TRGP vs ARGX Comparison
TRGP vs ARGX Comparison
Compare TRGP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRGP
- ARGX
- Stock Information
- Founded
- TRGP 2005
- ARGX 2008
- Country
- TRGP United States
- ARGX Netherlands
- Employees
- TRGP N/A
- ARGX N/A
- Industry
- TRGP Natural Gas Distribution
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRGP Utilities
- ARGX Health Care
- Exchange
- TRGP Nasdaq
- ARGX Nasdaq
- Market Cap
- TRGP 34.6B
- ARGX 40.4B
- IPO Year
- TRGP 2010
- ARGX 2017
- Fundamental
- Price
- TRGP $159.58
- ARGX $549.65
- Analyst Decision
- TRGP Strong Buy
- ARGX Strong Buy
- Analyst Count
- TRGP 18
- ARGX 20
- Target Price
- TRGP $198.83
- ARGX $698.22
- AVG Volume (30 Days)
- TRGP 2.3M
- ARGX 423.4K
- Earning Date
- TRGP 05-01-2025
- ARGX 05-08-2025
- Dividend Yield
- TRGP 2.50%
- ARGX N/A
- EPS Growth
- TRGP 11.70
- ARGX N/A
- EPS
- TRGP 5.44
- ARGX 15.94
- Revenue
- TRGP $16,380,600,000.00
- ARGX $2,643,062,000.00
- Revenue This Year
- TRGP $42.86
- ARGX $60.97
- Revenue Next Year
- TRGP $8.54
- ARGX $31.50
- P/E Ratio
- TRGP $29.41
- ARGX $32.07
- Revenue Growth
- TRGP 1.73
- ARGX 82.13
- 52 Week Low
- TRGP $112.27
- ARGX $352.77
- 52 Week High
- TRGP $218.51
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- TRGP 38.39
- ARGX 36.21
- Support Level
- TRGP $154.45
- ARGX $529.11
- Resistance Level
- TRGP $163.29
- ARGX $658.93
- Average True Range (ATR)
- TRGP 5.34
- ARGX 17.55
- MACD
- TRGP -0.53
- ARGX -6.04
- Stochastic Oscillator
- TRGP 20.20
- ARGX 15.82
About TRGP Targa Resources Inc.
Targa Resources is a midstream firm that primarily operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.